Pluri and Remedy Cell Expand Manufacturing Agreement for Fibrotic Therapeutics.

Monday, Dec 22, 2025 7:06 am ET1min read
PLUR--

Pluri, Inc. has expanded its manufacturing agreement with Remedy Cell Ltd. The agreement involves Pluri's Contract Development and Manufacturing Organization (CDMO) division implementing Remedy Cell's proprietary manufacturing process in Pluri's GMP facility. The collaboration has resulted in successful GMP training and qualification for the Remedy Cell manufacturing team, as well as engineering runs to confirm process robustness and scalability.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet